Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)

被引：20

作者：

Facon, Thierry ^{[1
]}

Lee, Jae Hoon ^{[2
]}

Moreau, Philippe ^{[3
]}

Niesvizky, Ruben ^{[4
]}

Dimopoulos, Meletios Athanasios ^{[5
]}

Hajek, Roman ^{[6
,7
]}

Osman, Muhtarjan ^{[8
]}

Aggarwal, Sanjay ^{[8
]}

Klippel, Zandra ^{[8
]}

Miguel, Jesus San ^{[9
]}

机构：

[1] Ctr Hosp Reg Univ Lille, Lille, France

[2] Gachon Univ, Gil Hosp, Seongnam, South Korea

[3] CHU Nantes, Univ Hosp Hotel Dieu HME, Nantes, France

[4] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA

[5] Natl & Kapodistraian Univ Athens, Sch Med, Athens, Greece

[6] Univ Hosp Ostrava, Ostrava, Czech Republic

[7] Fac Med Ostrava, Ostrava, Czech Republic

[8] Amgen Inc, Thousand Oaks, CA 91320 USA

[9] Univ Navarra, Navarra, Spain

来源：

关键词：

D O I：

10.1016/j.clml.2017.03.045

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OP-044

引用

页码：E26 / E27

页数：2